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Abstract
CD4+ regulatory T cells (Tregs) are essential for the maintenance of the immune system’s equilibrium, by dampening the
activation of potential auto-reactive T cells and avoiding excessive immune activation. To correctly perform their function,
Tregs must be maintained at the right proportion with respect to effector T cells. Since this equilibrium is frequently
disrupted in individuals infected with the human immunodeficiency virus (HIV), we hypothesize that its deregulation could
hamper immune reconstitution in patients with poor CD4+ T cell recovery under highly active antiretroviral therapy
(HAART). We analysed Tregs percentages amongst CD4+ T cells in 53 HIV-infected patients under HAART, with suppression
of viral replication and distinct levels of immune reconstitution. As controls, 51 healthy individuals were also analysed. We
observed that amongst the patients with Nadir values (the lowest CD4+ T cell counts achieved) ,200 cells/mL, the
individuals with high Tregs percentages ($10% of total CD4+ T cells) had the worse CD4+ T cell reconstitution. In
accordance, the well-described direct correlation between the Nadir value and CD4+ T cell reconstitution is clearly more
evident in individuals with high Tregs proportions. Furthermore, we observed a strong negative correlation between Tregs
percentages and CD4+ T cell recovery among immunological non-responder HIV+ individuals. All together, this work shows
that high Tregs frequency is an important factor associated with sub-optimal CD4+ T cell recovery. This is particularly
relevant for immunological non-responders with low Nadir values. Our results suggest that the Tregs proportion might be
of clinical relevance to define cut-offs for HAART initiation.
Citation: Horta A, Nobrega C, Amorim-Machado P, Coutinho-Teixeira V, Barreira-Silva P, et al. (2013) Poor Immune Reconstitution in HIV-Infected Patients
Associates with High Percentage of Regulatory CD4+ T Cells. PLoS ONE 8(2): e57336. doi:10.1371/journal.pone.0057336
Editor: Derya Unutmaz, New York University, United States of America
Received September 28, 2012; Accepted January 21, 2013; Published February 20, 2013
Copyright:  2013 Horta et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Portuguese Foundation for Science and Technology (FCT; PIC/IC/83313/2007; http://www.fct.pt/apoios/projectos/
consulta/vglobal_projecto.phtml.en?idProjecto = 83313&idElemConcurso = 1689). CN and PB-S received a fellowship from FCT (SFRH/BPD/65380/2009 and SFRH/
BD/73544/2010, respectively). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mcorreianeves@ecsaude.uminho.pt
. These authors contributed equally to this work.
Introduction
Infection with HIV initiates a series of events that ultimately
lead to profound immunosuppression, caused by functional
abnormalities in the immune system, mainly due to severe
depletion of CD4+ T cells [1].
The introduction of HAART has led to very important declines
in both mortality and morbidity due to HIV infection [2];
however, even though many patients steadily recover their CD4+
T cell compartment over several years post-HAART initiation, the
degree of immune recovery achieved is highly variable. On this,
studies indicate that even after several years of treatment, a
proportion of patients (from 15% to 40%) feature abnormally low
CD4+ T cell counts despite suppression of HIV replication
[3,4,5,6]. This group of individuals is referred to as immunological
discordants or non-responders and, unlike full responders, they are
at increased risk of clinical progression to acquired immunodefi-
ciency syndrome (AIDS)-related and non-related illnesses and
death [2].
Sub-optimal CD4+ T cell recovery may result from excessive/
premature cell death, decreased peripheral proliferation and/or
reduced production of these cells by the thymus. Several factors
have been suggested to contribute to this limited ability of the
CD4+ T cell compartment to normalise (reviewed in [7]) such as
advanced age [8], low baseline CD4+ T cell counts [6,8,9],
residual HIV replication [10], chronic immune activation [11],
abrogated thymic function [12,13], gender [14,15] and genetic
polymorphisms associated with increased programmed cell death
[16,17]. While all these factors are definitely relevant in
establishing different immune reconstitution profiles, there may
be other factors also contributing to this process [7].
Tregs are essential for the maintenance of self-tolerance and
immune homeostasis [18] and have been widely studied in the
context of HIV infection. Most studies have focused on whether or
not these cells are directly infected by HIV, to what extent are they
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depleted/expanded, and their role during the course of disease
progression from HIV infection to AIDS. The ability of HIV to
directly infect Tregs is still a subject of debate. Whilst it has been
reported that they are susceptible to HIV infection in vitro [19,20],
other studies showed that exposure of Tregs to HIV selectively
promotes their survival via a CD4-gp120–dependent pathway
[21]. Moreover, the accumulation of Tregs in the gut or in the
tonsils of HAART-naı¨ve HIV+ patients also argues against
increased killing of these cells in compartments where viral
replication is occurring [22,23].
During the course of disease progression in HAART-naı¨ve
patients, Tregs seems to act as a double-edged sword. On one
hand frequencies of these cells have been shown to negatively
correlate with the levels of immune activation [24,25,26,27,28],
which is one of the key contributors to HIV disease progression
[29,30,31]; on the other hand, high levels of Tregs have also been
linked with suppression of HIV-specific CD4+ and CD8+ T cell
activity and, thus, in this way Tregs could be linked to a worse
disease prognosis [32,33,34]. Tregs have also been investigated in
the context of HAART-associated immune reconstitution, al-
though to a much lesser extent. Results so far also lack a
consensus. Some authors found elevated levels of Tregs in
aviremic HIV+ patients in comparison to healthy controls
[35,36,37,38], whilst others described Tregs frequencies as
following a ‘‘biphasic curve’’ during the first year of HAART
[39], with an initial increase and a subsequent return to levels
comparable to controls [22,23,39]. The observation that the
proportion of Tregs in HAART-treated aviremic HIV+ individuals
is quite diverse prompted us to explore whether distinct values
were associated with differences in CD4+ T cell recovery. Thus,
we investigated how the percentage of Tregs within CD4+ T cells
correlated with CD4+ T cell count recovery and other parameters
of immune reconstitution in HAART-treated HIV+ individuals.
Understanding the mechanisms that limit T cell recovery during
HAART is essential to help adjust guidelines for HAART
initiation, and to prompt investigation of complementary immune
therapies that could enhance immune reconstitution.
Materials and Methods
Ethics Statement
This study was approved by the institutional review board of the
Hospital Joaquim Urbano under the protocol number 168/CES
[addenda number 127/12 (NA-DEFI/089-CES)]. Study subjects
gave written, informed consent prior to their participation.
Study population
A cross-sectional study was performed with 53 HIV+ individuals
recruited from Hospital Joaquim Urbano, Porto, Portugal (4368
years old, range 31 to 58 years old; 79% were males) and 51
healthy individuals recruited from the same hospital and from the
Life and Health Sciences Research Institute, Braga, Portugal
(3969 years old, range 27 to 56 years old; 49% were males).
Inclusion criteria for HIV+ individuals were: infection with HIV-1;
receiving HAART for at least 1 year; being regular on HAART
compliance (with no history of irregular compliance in the past);
plasma viral loads #50 copies HIV RNA/mL; and baseline CD4+
T cell counts #500 cells/mL. Information regarding patient’s
gender, hepatitis C virus (HCV) co-infection, HAART compli-
ance, baseline CD4+ T cell counts, Nadir value and actual CD4+
T cell counts was collected by patients’ physician. CD4+ T cell
counts were obtained by a reference laboratory. CD4+ T cell count
progression for each individual were calculated by subtracting the
baseline CD4+ T cell counts (immediately before HAART
initiation) from the actual CD4+ T cell counts. The CD4+ T cell
slopes (b1) for each individual during the first 12 months of
HAART were calculated by the least square estimation method
using MO Excel (CD4+ T cell count = b0+b16time; b0 being the
CD4+ T cell counts at 0 months of HAART); analysis was
restricted to those subjects who had at least three CD4+ T cell
measurements during the first year after HAART initiation.
Flow cytometry
All samples were processed for flow cytometric analysis on the
day the blood was collected. To stain for cell surface molecules
100 mL of whole blood were incubated with a defined set of
antibodies for 15 min at room temperature, followed by 15 min
with FACS Lysis Buffer (BD Biosciences), washed and acquired.
To determine the expression of the intracellular marker FOXP3, 2
million peripheral blood mononuclear cells (PBMCs), obtained
from heparinized blood by Histopaque 1077 (Sigma-Aldrich)
gradient centrifugation, were stained for cell surface markers for
20 min, washed, fixed, permeabilized and stained using the
FOXP3 Staining Buffer Set (eBiosciences). Antibodies used were
anti-CD4 (clone RPA-T4; BD Biosciences), anti-CD3 (clone
OKT3 or UCHT1), anti-CD45RO (clone UCHL1), anti-HLA-
DR (clone L243), anti-CD127 (clone PHCD127), anti-CD25
(clone BC96, all from Biolegend) and anti-FOXP3 (clone
PCH101, eBiosciences). Optimal concentration was determined
for each antibody by testing serial dilutions. All samples were
acquired on a BD LSR II flow cytometer using FACS DIVA
software (Becton and Dickinson, NJ, USA) and data were analysed
using FlowJo Software (Tree Star, OR, USA).
Statistical analysis
The normality assumption for parametric tests was tested using
the Kolmogorov-Smirnov test (with Dallal-Wilkinson-Lilliefor
Significance Correction); since the Tregs percentages from HIV+
individuals did not follow a normal distribution all tests applied
were non-parametric. Groups’ medians, variances and proportions
were compared using the Mann-Whitney, Levene’s and Chi-
square tests, respectively. Spearman’s rank correlation coefficient
was performed to assess the correlation between two variables. P-
values less than 0.05 were considered statistically significant.
Results and Discussion
Heterogeneous distribution of Tregs percentages among
HIV+ individuals under HAART
Human Tregs were first identified on the basis of their high-
level expression of CD25 (the IL-2Ra chain) [40,41,42] and
subsequently by the expression of the Forkhead-box transcription
factor FOXP3 [43,44]. However, further human studies have
shown that activated CD4+ T cells also up-regulate the expression
of CD25 and can transiently express FOXP3 [45,46]. More
recently, it was shown that Tregs express low levels of CD127 (the
IL-7Ra chain), and therefore this molecule is considered useful as
an additional marker to identify this population [47,48,49,50].
Even though the utility of these, and other putative Tregs markers,
is still debated, they currently represent the best available markers
to identify this cell subset. With this in mind, we chose to identify
Tregs within CD4+ T cells (CD3+CD4+) as the CD127lowCD25-
highFOXP3+ population (Figure 1A).
Using this gating strategy to define Tregs the vast majority of
our control individuals (75%) featured Tregs percentages between
5% and 10% (Figure 1B), frequencies similar to those reported by
other groups using the same markers and gating strategy [51]. By
comparing the median Tregs percentages no differences were
Tregs Impact on Immune Reconstitution
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observed between the HIV+ and control individuals (p = 0.8250,
Mann-Whitney test; Figure 1B). However, the range of Tregs
percentages observed was higher amongst HIV+ individuals
(p = 0.0020, Levene’s test; Figure 1B). It was interesting also to
note that the number of individuals with Tregs percentages $10%
was significantly higher in the HIV cohort as compared to control
(p = 0.0313, Chi-Square test; Figure 1C).
As studies of HAART-treated HIV+ individuals have yielded
conflicting data regarding Tregs percentages
[22,23,35,36,37,38,39], we sought to understand if other variables
could be influencing this parameter. We found that neither
individual’s age, number of years in therapy, overall immune
activation or infection by the hepatitis C virus (HCV) impacted
upon Tregs percentage in our HIV population (Figure S1).
Overall, whilst there were no differences in the median
percentage of Tregs in HIV+ and control individuals, there was
a wider distribution of Tregs percentages among HIV+ individuals,
ranging from 3% to 19%. Furthermore, Tregs frequencies were
not related to age, number of years of treatment, overall immune
activation or infection by HCV (Figure S1).
The majority of HIV+ individuals with high Tregs
percentages featured low Nadir value and incomplete
CD4+ T cell recovery
To evaluate whether distinct Tregs percentages were related to
different degrees of CD4+ T cell recovery amongst HAART-
treated HIV+ individuals, we assessed potential correlations
between distinct parameters to evaluate CD4+ T cell reconstitution
and Tregs percentages. As shown in Figure 2A, we found no
correlation between Tregs percentages and CD4+ T cell counts,
CD4+ T cell progression or CD4+ T cell slope (R =20.2130 and
p = 0.1270; R =20.2409 and p = 0.0823; R =20.1836 and
p = 0.2633, respectively, Spearman’s correlation). While there is
no clear correlation between the CD4+ T cell reconstitution and
Tregs percentage, as previously reported by others [37,39], it is
interesting to note that amongst HIV+ individuals with high Tregs
proportions ($10%) the majority featured low CD4+ T cell
numbers (,500 cells/mL), low CD4+ T cell recovery and low
CD4+ T cell slope (Figure 2A).
To further dissect the link between low CD4+ T cell counts and
high Tregs percentages in HIV+ individuals we re-assessed the
relationship between these two variables taking into account the
gender, number of years on treatment and the Nadir value, all of
which are factors known to influence immune reconstitution
[3,4,5,15,52,53]. No clear correlations were observed between the
Tregs percentages and CD4+ T cell counts when patient’s gender
(R =20.2480 and p = 0.1090 for males; R =20.2480 and
p = 0.4920 for females, Spearman’s correlation), years of therapy
(R =20.0772 and p = 0.7534 for ,5 y HAART; R =20.2598
and p = 0.1379 for $5 y HAART, Spearman’s correlation) and
the Nadir value (R =20.07719 and p = 0.0648 for ,200 cells/mL,
R = 0.0,0963 and p = 0.6893 for $200 cells/mL, Spearman’s
correlation) were taken in consideration (Figure 2B).
Of notice, we observed that almost all individuals with Tregs
percentage $10% and CD4+ T cell counts #500 cells/mL had
Nadir values ,200 cells/mL (Figure 2B). Since the Nadir value has
been considered one of the key factors influencing immune
reconstitution [3,4,5], we considered relevant to further explore
this association. To do so we analysed CD4+ T cell counts in HIV+
individuals divided on the basis of their Nadir values (,200 and
$200 cells/mL) and subdivided according to their Tregs frequency
(,10%, Figure 3A). As previously reported [3,4,5], we observed
that individuals with low Nadir values (,200 cells/mL) had lower
CD4+ T cell counts upon treatment (p = 0.0234, Mann-Whitney
test, Figure 3A). Interestingly, this difference lost statistical
significance when only those individuals with Tregs percentages
,10% were analysed (p = 0.1934 by Mann-Whitney test,
Figure 3A).To address the influence of Tregs percentages on the
well-established correlation between CD4+ T cell recovery and
Nadir value [3,4,5], a correlation between these two variables
separating the individuals according to the Tregs percentages was
performed. As shown previously by others we observed that CD4+
T cell counts positively correlate with the Nadir value when all
HIV+ individuals are considered (R = 0.4481 and p = 0.0008,
Spearman’s correlation; Figure 3B). Of interest this correlation
Figure 1. High variability of Tregs percentages in HIV+ individuals. A. Representative dot plots from an HIV+ individual illustrating the gating
strategy for Tregs analysis. Lymphocytes (selected according to FSC and SSC) were gated on CD3+CD4+ cells, on low or no expression of CD127 and
on the expression of FOXP3 and high levels of CD25. B. Tregs percentages amongst CD4+ T cells in control and HIV+ individuals. Each dot represents a
single individual and the lines the median Tregs percentages within CD4+ T cells. Dashed lines represent the range of Tregs percentages among total
CD4+ T cells described for healthy individuals (between 5% and 10%) [51]. C. Percentage of individuals with Tregs #5% and $10% in controls and
HIV+ individuals. P-value for the comparison of these proportions (Chi-square test) and the 95% confidence interval are depicted.
doi:10.1371/journal.pone.0057336.g001
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was much stronger when only those individuals with $10% Tregs
were taken into account (R = 0.8392 and p = 0.0006 by Spear-
man’s correlation; Figure 3B) indicating that CD4+ T cell recovery
of individuals with low Nadir is hampered by high proportions of
Tregs.
Results reported by Gaardbo et al. [36], who analysed a
correlation between CD4+ T cell counts and Tregs percentages in
patients sub-divided according to baseline CD4+ T cell counts (,
and .200 cells/mL), did not find any differences. Their analysis
focused on HIV+ patients with over 2 years of treatment. Since we
have observed that time in treatment seems to have no impact on
the CD4+ T cell counts vs. Tregs proportion relation, the
discrepancy is most likely due to the use of different markers to
define Tregs or to the fact that they used baseline CD4+ counts
instead of Nadir values.
Strong correlation between Tregs percentages and CD4+
T cell counts progression in immunologically non-
responders HIV+ individuals
While the observation that some individuals are unable to
reconstitute the CD4+ T cell numbers to normal values, even after
several years of therapy and suppression of viral replication, there
is still a lack of consensus on the definition of immunological non-
responder individuals [7]. The most well accepted definition for
immunological non-responders patients are the ones whose CD4+
T cell counts remained below a threshold (from 350 to 500 cells/
mL) after a variable period of time of treatment (from 4 to 7 years)
[3,4,5]. Considering as immunological non-responders the indi-
viduals under regular HAART for at least 5 years and whose
CD4+ T cell counts were ,500 cells/mL (14 out of 53 individuals
in our population), we observed a strong correlation between
Tregs percentages and CD4+ T cell progression (R =20.7765 and
p = 0.0004, Spearman’s correlation, Figure 4), which strengthens
the observed association between high Tregs percentage and poor
CD4+ T cell reconstitution.
The biological processes that could lead to different Tregs
percentages in HIV+ individuals remain unclear. Whilst some
studies have shown that Tregs are permissive to HIV infection in
vitro [19,20], which could lead to the depletion of this subset in
HIV+ individuals, others have shown that HIV selectively
promotes Tregs survival by reducing apoptosis levels in this
subset, and thereby increasing their proportion within the CD4+ T
Figure 2. HIV+ individuals with high Tregs percentages feature low CD4+ T cell counts and Nadir values. A. Percentages of Tregs
amongst HIV+ individuals were plotted against CD4+ T cell counts, CD4+ T cell progression and CD4+ T cell slope (for the first year of HAART). Each dot
represents a single individual. B. Tregs percentages were plotted against CD4+ T cell counts in HIV+ individuals grouped by gender) number of years
under HAART and the Nadir value.
doi:10.1371/journal.pone.0057336.g002
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cell pool as a whole [21]. Several hypotheses have been put
forward in order to explain the observed differences in Tregs
percentages, such as increased Tregs thymopoiesis [37] or even
conversion of conventional CD4+ T cells to Tregs [54,55]. Further
studies are still needed in order to fully understand Tregs kinetics
during immune reconstitution in HAART-treated HIV+ individ-
uals.
Altogether, our data show that high proportions of Tregs during
treatment in individuals who reached low Nadir values (,200
CD4+ T cells/mL) have a synergistic/cumulative negative associ-
ation with incomplete CD4+ T cell recovery. While the clear
association of high percentage of Tregs with low Nadir and
incomplete reconstitution would suggest a potential negative
impact of Tregs on CD4+ T cell recovery, it cannot be excluded
the possibility that Tregs, in individuals with incomplete immune
reconstitution, play an important role preventing excessive
expansions of oligoclonal populations. This could be of importance
to better decide when to start treatment. If during the course of
HIV infection an individual already has a high Tregs percentage,
our results would support the need for HAART initiation even if
CD4+ T cells counts remain relatively high. Further studies
involving longitudinal follow up are needed in order to fully
understand how the high percentage of Tregs abrogates the CD4+
T cells recovery. Moreover, these studies could also help defining
the parameters that synergise with high Tregs frequencies and low
Nadir for sub-optimal T cell recovery.
Supporting Information
Figure S1 Tregs percentages are not affected by HCV
infection, age, time in treatment or immune activation.
A. Tregs percentages were compared in HIV+ individuals when
divided according to co-infection with HCV (p = 0.1250, Mann-
Whitney test). B. Relationship between the Tregs percentages and
age (left panel; R =20.1520, p = 0.2773; Spearman’s correlation),
years in therapy (middle panel; R =20.0682, p = 0.6277; Spear-
man’s correlation) and overall immune activation (right panel;
R = 0.1400, p = 0.3660; Spearman’s correlation). Each dot
represents a single individual.
(TIF)
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Figure 3. Individuals with high Tregs percentages feature the strongest correlation between CD4+ counts and Nadir values. A. HIV+
individuals were subdivided according to their Nadir counts (,200 and $200 cells/mL) and grouped according to Tregs percentages (all individuals
and individuals with ,10% Tregs) and the CD4+ T cell counts are shown for each group. Each dot represents a single individual and the line the
median value for each group. P-value for the comparison of the CD4+ T cell counts is indicated (Mann-Whitney test). B. Scatter plots illustrating the
correlation between Nadir value and CD4+ T cell counts during HAART. Each dot represents a single individual. P-value for the correlation between
CD4+ T cell counts and the Nadir value is shown (Spearman’s correlation).
doi:10.1371/journal.pone.0057336.g003
Figure 4. Immunological non-responders present a strong
correlation between Tregs percentages and CD4+ T cell
progression. Scatter plot illustrating the correlation between Tregs
percentages and CD4+ T cell progression. Patients were selected on the
basis of being under HAART for at least 5 years and whose actual CD4+
T cell counts are ,500 cells/mL or .500 cells/mL. Each dot represents a
single individual.
doi:10.1371/journal.pone.0057336.g004
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